Oncolytic Virus Therapy — Using a Virus to Attack Cancer

A virus is engineered so that it can only replicate properly inside cancer cells. It multiplies there until the cell bursts. The burst releases tumour proteins and danger signals into the surrounding tissue. Immune cells that had been ignoring the tumour move in. The killing is the beginning; the immune reaction is the point.

Two things happen at once, and only one of them is obvious. The obvious part is that cancer cells die. The part that matters more is what the dying leaves behind.

A tumour that the immune system has learned to ignore is described as “cold”. There is nothing for immune cells to react to, so they stay away. A virus bursting cells open changes that in one step. Fragments of the tumour are suddenly on display. Alongside them are the alarm signals a body reserves for an infection. The immune system arrives expecting a virus and finds the cancer.

Cancer cells are also unusually hospitable to a virus. Normal cells carry interferon defences that shut a virus down quickly. Many cancer cells have damaged those same defences on their way to becoming cancer. That damage helped them grow. It is also what makes them easier for an engineered virus to live in.

This is why the field is often described as immunotherapy rather than as an antiviral treatment in reverse. The virus is a way of getting the immune system to look. Whether it then does something useful is a separate question, and it is the question the research is still answering.

This page exists because the curiosity is high and the availability is low. Saying so plainly is more useful than a hopeful paragraph that leaves you making enquiries for a treatment you cannot get. Here is what does exist, and where.

• A modified herpes simplex virus type 1 therapy — approved in the United States and Europe since 2015, for melanoma lesions in the skin and lymph nodes that a needle can reach. It is injected into the lesion itself, not into a vein.
• An adenovirus-based oncolytic therapy — approved in China for head and neck cancer, used alongside chemotherapy. It has not been adopted as standard care outside that setting.
• A modified herpes virus for malignant glioma — granted conditional approval in Japan in 2021, injected into the brain tumour by a neurosurgeon under image guidance.
• Everything else — clinical trials. Promising early results appear regularly in the press. Early results are not approval, and approval elsewhere is not availability here.

If someone in India offers you “virus therapy”, ask for two things in writing before any money changes hands. First, the CDSCO approval for that specific product in India. Second, if it is described as a trial, the clinical trials registry number and the name of the ethics committee that cleared it. A legitimate trial can produce both in a day. An unproven offer will produce neither, and will usually ask you to decide quickly.

Approval status differs by country and changes over time. Where a status is uncertain, this page says it is uncertain rather than asserting either way. Confirm anything specific to you with your treating oncologist.

Classes and mechanisms are described here deliberately, without naming products, and no comparison of effectiveness between products is made. Approval status is country-specific and can change.

1. 1

   A lesion is chosen

   A skin nodule, a lymph node, or a deeper deposit that can be reached under ultrasound or CT guidance. If nothing can be safely injected, this treatment does not apply.

2. 2

   The dose goes into the tumour

   The volume depends on the size of the lesion. It is a day-care procedure in the settings where it is approved, and the injection itself takes minutes.

3. 3

   Flu-like symptoms follow

   Fever, chills, tiredness and soreness at the site, usually settling in a day or two. This is the immune system reacting, which is what the treatment is asking it to do.

4. 4

   Injections repeat on a schedule

   Typically every two to three weeks, for as long as there is a lesion worth injecting and the treating team judges that it is still helping. It is not a single dose.

5. 5

   Handling rules apply at home

   Dressings cover the site. Contact with pregnant women, newborns and anyone significantly immunosuppressed is restricted for a period. The team gives written instructions, and they are not optional.

Because a live modified organism is being given, people who are themselves significantly immunosuppressed are generally not candidates. Eligibility is a clinical judgement made on your reports, not on a web page.

CION does not administer or stock CAR-T or any cell therapy product. Immunotherapy that CION does provide is given as day care at our centres, and response-assessment PET-CT is coordinated at partner imaging centres.

• Flu-like reactions are the common ones — fever, chills, fatigue and pain at the injection site, usually settling within a day or two. Tell your team about a fever anyway; they decide what it is, not you.
• It is a live modified organism — transmission precautions apply at home, herpes-based strains carry a small risk of a herpetic infection at the site, and people who are significantly immunosuppressed are generally not candidates.
• A tumour can look larger before it looks smaller — inflammation swells the lesion. Scans have to be read with immunotherapy response criteria in mind, by a radiologist who knows what was given.
• Delivery is the unsolved problem — a virus given into a vein is largely neutralised before it arrives, which is why almost every approved use is an injection into the tumour itself.
• Long-term evidence is immature — durability of benefit, late immune-related effects and the best combinations are all still being established. Honest sources say so, and this page says so too.

Clinical trials are how these questions get answered. This page is informational only. It does not recruit for any trial and cannot promise anyone a place in one. If a trial interests you, ask your treating oncologist to look for a registered study that matches your diagnosis.

• Checkpoint Inhibitors: How Releasing the Brakes on Immunity Works — the class most Indian patients are actually offered, and the one most often paired with an oncolytic virus in current research.
• CAR-T Cell Therapy: Reprogramming Your Own Cells — the other treatment people mean when they say “something living is being given”. CION refers for this rather than providing it.
• Tumour-Infiltrating Lymphocyte (TIL) Therapy — growing the immune cells already inside a tumour, a different answer to the same problem this page describes.
• Immunotherapy at CION Cancer Clinics — the hub page, covering eligibility, biomarker testing, day-care administration and cost.

This page is general information and does not replace a consultation. It names drug classes and mechanisms only, not products, and makes no comparison of effectiveness between products. Regulatory approval status is country-specific and changes over time; confirm anything specific to your case with your treating oncologist.

Curiosity about virus therapy is reasonable

It is a fair question and it deserves a straight answer rather than a brush-off. Our team will take the time to explain what exists, what is being tested, and what is simply not available here.